BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28690315)

  • 1. Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Jain N; Zhu H; Khashab T; Ye Q; George B; Mathur R; Singh RK; Berkova Z; Wise JF; Braun FK; Wang X; Patel K; Xu-Monette ZY; Courty J; Young KH; Sehgal L; Samaniego F
    Leukemia; 2018 Mar; 32(3):663-674. PubMed ID: 28690315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
    Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
    Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
    Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
    Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.
    Krust B; El Khoury D; Nondier I; Soundaramourty C; Hovanessian AG
    BMC Cancer; 2011 Aug; 11():333. PubMed ID: 21812966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
    Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
    PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
    Mosafer J; Teymouri M; Abnous K; Tafaghodi M; Ramezani M
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():123-133. PubMed ID: 28024568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
    Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
    Wu J; Song C; Jiang C; Shen X; Qiao Q; Hu Y
    Mol Pharm; 2013 Oct; 10(10):3555-63. PubMed ID: 23679916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
    Reyes-Reyes EM; Teng Y; Bates PJ
    Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
    Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
    Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
    Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
    Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
    Sharma VR; Thomas SD; Miller DM; Rezzoug F
    Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
    Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
    Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleolar localization of aprataxin is dependent on interaction with nucleolin and on active ribosomal DNA transcription.
    Becherel OJ; Gueven N; Birrell GW; Schreiber V; Suraweera A; Jakob B; Taucher-Scholz G; Lavin MF
    Hum Mol Genet; 2006 Jul; 15(14):2239-49. PubMed ID: 16777843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response.
    Lim KH; Park JJ; Gu BH; Kim JO; Park SG; Baek KH
    Sci Rep; 2015 Aug; 5():12793. PubMed ID: 26238070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
    Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
    Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.